The surgeon found Sarah Burke in the hospital waiting room, her husband and two children by her side, and delivered the kind of news that breaks a life in two.
She had breast cancer.
Then came the second blow: It had already begun to spread, and the cancer could be deadly.
To add to the agony, just six months earlier, Sarah had undergone a routine mammogram – the gold-standard screening test offered to millions of women to pick up breast cancer at the earliest stages when it’s far easier to treat.
The test had shown nothing.
Now, here she was, being told she had an advanced, difficult-to-cure disease.
The implication was as devastating as the diagnosis itself. This hadn’t appeared overnight. It had been there, growing unseen, for some time.
The question that haunts Sarah, now 50, is simple: How could it have been missed?
Sarah Burke was a picture of health before being diagnosed with cancer
Burke, pictured with husband Jarrin, 45, and children Jackson, 22, and Emily, 18
But what makes her story all the more troubling is that she knew she wasn’t ever a straightforward case.
For years, she had been told she had dense breasts – a physical trait that can make cancers far harder to detect on routine scans.
Breast density has nothing to do with breast size, how they look or how they feel. It refers instead to how they appear on a mammogram – a type of X-ray used to spot tumors.
Breasts are made up of fatty tissue and fibroglandular tissue (milk ducts and supportive structures). On a mammogram, fat shows up as dark space while the other denser tissue appears white.
The problem is that tumors also appear white.
In women with dense breasts, the two can blend together, making it significantly easier for cancer to hide in plain sight.
It’s a surprisingly common issue. Around 40 to 50 percent of women have dense breasts, and for those at the highest levels of density, the risk of developing breast cancer is up to six times higher than average.
They are also more likely to have cancers diagnosed at a later stage.
Burke, from Billings, Montana, fell into that category.
For a decade, she had been called back for repeat scans after inconclusive mammograms – false alarms caused by the very density that also masked her tumor.
‘I feel things all the time, and I don’t even know what I’m feeling for anymore,’ she said. ‘After a while, you just start to dismiss it.’
Crucially, she had asked a number of times about having an additional MRI scan – a more sensitive imaging test that does not rely on X-rays and is better at detecting tumors in dense breast tissue.
But she was never offered one.
Her experience highlights a growing tension in breast cancer screening.
In the US, new rules introduced in 2024 mean that all women must now be told if they have dense breasts following a mammogram – a major shift designed to ensure patients are aware of the limitations of standard screening.
Yet there is currently no national consensus on what should happen next.
The US Preventive Services Task Force – which sets widely followed screening recommendations – says there is ‘insufficient evidence’ to recommend additional routine screening, such as MRI or ultrasound, for women with dense breasts.
In practice, this means many women are left in limbo: told they have a risk factor that can both increase their chances of cancer and make it harder to detect, but not routinely offered the tests that might overcome that problem.
Insurance coverage for MRI scans is often restricted to those deemed very high risk, such as women with strong genetic predispositions, putting it out of reach for many others.
Burke, despite years of inconclusive scans and known dense breast tissue, did not meet that threshold.
So she carried on with regular mammograms.
Then, in March 2024, she felt a lump. At first, she almost ignored it.
Sarah had been through this cycle so many times before – the callbacks, the worry, the eventual reassurance – that it had become, in her words, ‘just part of life.’
But by April, it had grown. This time, she knew it was different.
Within days, she was sent for a battery of tests – ultrasounds, biopsies and, finally, an MRI.
This time there was little room for doubt. Cancer was present in both breasts and in the lymph nodes under her arms – part of the body’s drainage system where this type of cancer often spreads first once it escapes the breast itself.
In this case, doctors typically focus particularly on what’s known as the ‘sentinel’ lymph node – the first node that cancer cells are most likely to reach. If that node contains cancer, it can be a sign the disease has already begun to travel beyond its original site.
In Burke’s case, it had.
Today, Burke is cancer-free, and she can enjoy time with her family
‘You think, “I don’t have cancer – they pull me back in here all the time and it’s nothing,”‘ Sarah said. ‘After a while, you just get to a point where it’s annoying… and then it wasn’t.’
Despite her long history of false positives, and despite her known breast density, she was never escalated to more advanced screening.
Part of the reason lies in how risk is defined.
Doctors had calculated Burke’s lifetime risk of breast cancer at around eight percent – not high enough to qualify for routine MRIs.
She was, before her diagnosis, a picture of health. Burke grew up on a farm, ate a healthy, organic diet, didn’t smoke and had a glass of wine only now and then.
Crucially, she had no family history of cancer.
Her case highlights an uncomfortable reality: While dense breasts increase risk, they are still not always treated as a decisive factor when it comes to screening.
That dissonance is now the subject of growing debate.
Some experts argue that simply informing women they have dense breasts is not enough without clearer follow-up pathways.
Others caution that expanding MRI screening to all could overwhelm healthcare systems and lead to overdiagnosis, detecting slow-growing cancers that may never cause harm.
For patients, however, the distinction can feel academic.
Burke had spent a decade doing everything she was told – attending regular screenings, following up on concerns, trusting the system. Yet the cancer was still missed.
By the time it was found, treatment could not wait.
Her surgeon initially suggested delaying the operation until after her daughter’s graduation that summer, but Burke refused.
‘How do you sit for the next month with spiders under your skin?’ she said.
Five days later, a specialist flew in to operate.
The plan had been two lumpectomies – removing the tumors while preserving both breasts. But once surgeons began, it became clear the disease on the left side was too extensive.
Chemotherapy left Burke weak and exhausted
Sarah woke up having undergone a mastectomy on one side, a lumpectomy on the other, and with drains attached to her body.
Then came chemotherapy.
Her first drug was adriamycin – known among patients as ‘the red devil’ for its vivid color and punishing side effects. It works by damaging the DNA of cancer cells, preventing them from multiplying.
But it is not selective. Hair follicles, the lining of the gut and even the heart can be affected.
In rare cases – around one percent – it can trigger seizures, and Burke joined that small statistic.
‘I fell asleep, and the next thing I know, the paramedics were there asking me my name,’ she said. ‘I remember saying the wrong name.’
Her husband and children had watched it happen.
‘He thought I was dead,’ she said.
A scan after the seizure showed a small bright spot on her brain. Initially dismissed as inflammation, it was later interpreted by another doctor as a possible tumor – raising the prospect of brain surgery.
‘I remember thinking, “I hate me,”‘ Burke said.
She began planning her funeral.
Only after a third opinion – and another scan months later – did doctors conclude the lesion had disappeared.
‘It’s gone,’ her neurosurgeon told her.
The tears that followed, she said, were the first of relief.
Burke is now healthy enough to hike with her husband in Montana
By then, she had endured months of treatment. Further chemotherapy left her weak and exhausted. Radiation followed – 18 sessions stretching from Thanksgiving to Christmas Eve.
Because her cancer was fueled by estrogen – as around 70 to 80 percent of breast cancers are – doctors also prescribed hormone therapy to shut down her ovaries.
The injections came with their own toll, causing fatigue, bone pain and low mood. Each one cost thousands of dollars.
Eventually, she chose to surgically remove her ovaries and uterus instead.
Today, Burke is cancer-free.
Her hair has grown back; she exercises, eats well, spends time with her husband Jarrin and children Jackson and Emily, and has returned to a life that, at times, she feared she might lose.
Still, the experience has left a lasting mark – not just physically, but in how she views the system she once trusted.
‘I wish I had been a better advocate for myself,’ she said.
